IL89602A - Microencapsulated compositions for potentiating an immune response and methods for the preparation thereof - Google Patents

Microencapsulated compositions for potentiating an immune response and methods for the preparation thereof

Info

Publication number
IL89602A
IL89602A IL89602A IL8960289A IL89602A IL 89602 A IL89602 A IL 89602A IL 89602 A IL89602 A IL 89602A IL 8960289 A IL8960289 A IL 8960289A IL 89602 A IL89602 A IL 89602A
Authority
IL
Israel
Prior art keywords
potentiating
preparation
methods
immune response
microencapsulated compositions
Prior art date
Application number
IL89602A
Other languages
English (en)
Other versions
IL89602A0 (en
Original Assignee
Southern Research Institue
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL89602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Southern Research Institue, Uab Research Foundation filed Critical Southern Research Institue
Publication of IL89602A0 publication Critical patent/IL89602A0/xx
Publication of IL89602A publication Critical patent/IL89602A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Vending Machines For Individual Products (AREA)
  • Electrotherapy Devices (AREA)
IL89602A 1988-03-18 1989-03-14 Microencapsulated compositions for potentiating an immune response and methods for the preparation thereof IL89602A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/169,973 US5075109A (en) 1986-10-24 1988-03-18 Method of potentiating an immune response

Publications (2)

Publication Number Publication Date
IL89602A0 IL89602A0 (en) 1989-09-10
IL89602A true IL89602A (en) 1993-07-08

Family

ID=22617981

Family Applications (1)

Application Number Title Priority Date Filing Date
IL89602A IL89602A (en) 1988-03-18 1989-03-14 Microencapsulated compositions for potentiating an immune response and methods for the preparation thereof

Country Status (20)

Country Link
US (1) US5075109A (h)
EP (3) EP1181929A3 (h)
JP (1) JP2521827B2 (h)
KR (1) KR0126823B1 (h)
CN (3) CN1070697C (h)
AT (2) ATE253901T1 (h)
AU (1) AU633483B2 (h)
CA (1) CA1340692C (h)
DE (2) DE68929499T2 (h)
DK (1) DK175851B1 (h)
ES (2) ES2088890T3 (h)
GR (1) GR3020569T3 (h)
HK (1) HK38897A (h)
IE (1) IE83868B1 (h)
IL (1) IL89602A (h)
IN (1) IN169330B (h)
NZ (1) NZ228376A (h)
RU (3) RU2250102C2 (h)
WO (1) WO1989008449A1 (h)
ZA (1) ZA892103B (h)

Families Citing this family (651)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
AU639903B2 (en) * 1989-01-20 1993-08-12 University Of Melbourne, The Fibrinolysis
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
EP0471036B2 (en) * 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
AU642932B2 (en) * 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
CA2080477A1 (en) * 1990-04-24 1991-10-25 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
DE59007645D1 (de) * 1990-06-21 1994-12-08 Edith Dr Huland Verwendung zytokinhaltiger Aerosole und zytokinhaltige Aerosole selbst.
AU664365B2 (en) * 1991-04-02 1995-11-16 Access Pharmaceuticals Australia Pty Limited Oral delivery systems for microparticles
WO1992019263A1 (en) 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
JP3007687B2 (ja) * 1992-09-10 2000-02-07 チルドレンズ メディカル センター コーポレイション 局所麻酔剤の持続性送達のための生分解性ポリマーマトリックス
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
WO1994007469A1 (en) * 1992-09-25 1994-04-14 Dynagen, Inc. An immunobooster for delayed release of immunogen
AU5669894A (en) * 1992-11-16 1994-06-08 Corporation Of Mercer University Compositions using microencapsulated neutralizing antibodies
ES2095001T5 (es) * 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
DK0724432T3 (da) * 1993-10-22 2003-01-27 Genentech Inc Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
JPH09504523A (ja) * 1993-10-22 1997-05-06 ジェネンテク，インコーポレイテッド アジュバントのマイクロカプセル化方法および組成物
EP0724433B1 (en) * 1993-10-22 1998-12-30 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
PT729357E (pt) 1993-11-19 2005-06-30 Janssen Pharmaceutica Nv 1,2-bwenzazoles microencapsulados
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US6531156B1 (en) 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
FI970522L (fi) 1995-06-09 1997-04-07 Euro Celtique Sa Koostumukset ja menetelmät pidennetyn paikallisanestesian aikaansaamiseksi
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DK1203817T3 (da) 1995-09-01 2006-08-14 Corixa Corp Forbindelser og fremgangsmåder til immunterapi og diagnose af tuberkulose
EP0862419B2 (en) * 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0954301A4 (en) 1996-06-24 2006-03-08 Euro Celtique Sa SAFE METHODS OF LOCAL ANESTHESIA
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
ATE359831T1 (de) * 1997-01-22 2007-05-15 Zycos Inc Mikropartikel zur verabreichung von nukleinsaeuren
EP2284186A1 (en) 1997-02-12 2011-02-16 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2239801T3 (es) 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
CA2301587C (en) * 1997-08-29 2008-07-08 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
EP1579851A3 (en) * 1997-08-29 2009-09-02 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
EP1042360A2 (en) 1997-12-24 2000-10-11 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP2003201A3 (en) 1998-03-18 2008-12-31 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
TR200002938T2 (tr) 1998-04-07 2001-02-21 Corixa Corporation Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı
WO1999052708A1 (en) 1998-04-13 1999-10-21 Luminex Corporation Liquid labeling with fluorescent microparticles
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
ATE335510T1 (de) 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP2272859B1 (en) 1998-08-07 2014-10-22 University of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6264991B1 (en) 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
AU5441199A (en) 1998-09-01 2000-03-21 Elan Corporation, Plc Oral vaccine compositions
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP2277893A3 (en) 1998-12-08 2011-03-30 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
HK1041009B (en) 1998-12-30 2009-05-08 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
PL354348A1 (en) 1999-04-02 2004-01-12 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US20050158856A1 (en) * 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
WO2001017557A1 (en) 1999-09-03 2001-03-15 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
HUP0300054A3 (en) 2000-02-23 2012-09-28 Smithkline Beecham Biolog Tumour-specific animal proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ATE299696T1 (de) 2000-05-12 2005-08-15 Pharmacia & Upjohn Co Llc Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
ES2332444T3 (es) 2000-06-22 2010-02-05 University Of Iowa Research Foundation Combinacion de cpg y anticuerpos dirigidos contra cd19, cd20, cd22 o cd40 para el tratamiento o prevencion de cancer.
DE60134158D1 (de) 2000-06-28 2008-07-03 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
AU2001296800A1 (en) * 2000-10-06 2002-04-15 Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
EP2322929B1 (en) * 2000-11-27 2016-04-06 Minerva Biotechnologies Corporation diagnostics, drug screening and treatment for cancer
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
WO2002053190A2 (en) 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2452382A1 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US6746635B2 (en) * 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
ES2307779T3 (es) * 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.
EP1455593B1 (en) 2001-10-06 2013-07-24 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
ES2466024T3 (es) 2001-10-10 2014-06-09 Ratiopharm Gmbh Remodelación y glicoconjugación de factor de crecimiento de fibroblastos (FGF)
CA2472055A1 (en) * 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Improved mucosal vaccines and methods for using the same
EP1458362A4 (en) 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICLE FORM
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
WO2003049701A2 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
US20060062807A1 (en) 2001-12-11 2006-03-23 Marie-Anne Nahori Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
ATE494907T1 (de) 2002-07-18 2011-01-15 Univ Washington Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
WO2004035028A1 (fr) * 2002-10-17 2004-04-29 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Procede de production d'une forme microencapsulee d'un vaccin viral vivant
EP1556513B1 (en) * 2002-10-21 2010-04-28 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
EP1660535A2 (en) 2002-11-27 2006-05-31 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
NZ570201A (en) 2003-02-11 2011-03-31 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
FI1897548T4 (fi) 2003-02-28 2024-09-03 The Johns Hopkins University T-solujen säätely
US8524899B2 (en) * 2003-03-04 2013-09-03 California Institute Of Technology Alternative heterocycles for DNA recognition
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005019819A1 (en) 2003-08-20 2005-03-03 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
EP2377528B1 (en) 2003-06-12 2014-02-19 The Board of Regents of the University of Colorado Fatty acid metabolism inhibitors for use in the treatment of cancer
RS20050934A (en) 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
DE10329087B4 (de) * 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
SG135204A1 (en) * 2003-07-18 2007-09-28 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7063151B2 (en) * 2004-03-05 2006-06-20 Halliburton Energy Services, Inc. Methods of preparing and using coated particulates
CN101001874B (zh) 2004-04-21 2012-12-19 布赖汉姆妇女医院 聚-n-乙酰葡萄糖胺(pnag/dpnag)结合肽及其应用方法
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
DK1765294T3 (da) 2004-05-12 2008-11-10 Baxter Int Nukleinsyremikrokugler samt deres fremstilling og afgivelse
CN103393601A (zh) * 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
US20060264411A1 (en) * 2005-05-20 2006-11-23 Eldridge Gary R Control of biofilm formation
US20060014285A1 (en) * 2004-07-14 2006-01-19 Eldridge Gary R Methods and compositions for inhibiting biofilms
US7604978B2 (en) * 2004-07-14 2009-10-20 Sequoia Sciences, Inc. Inhibition of biofilm formation
EP2199801B1 (en) 2004-07-14 2013-05-29 The Regents of The University of California Biomarkers for early detection of ovarian cancer
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US9132116B2 (en) 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
EP1797183B1 (en) * 2004-09-02 2012-08-01 Yale University Regulation of oncogenes by micrornas
EP1797108A1 (en) 2004-09-14 2007-06-20 Gary R. Eldridge Compounds, compositions and methods for controlling biofilms and bacterial infections
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
RU2419628C2 (ru) * 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
AU2005294129B2 (en) 2004-10-08 2010-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonymous codons
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
MX2007006833A (es) 2004-12-10 2007-10-08 Talima Therapeutics Inc Composiciones y metodos para tratar condiciones de la unidad de una.
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
EP2385038A1 (en) 2005-02-25 2011-11-09 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
US7851189B2 (en) * 2005-03-07 2010-12-14 Boston Scientific Scimed, Inc. Microencapsulated compositions for endoluminal tissue engineering
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
CA2610292C (en) 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
US20090022755A1 (en) 2005-03-31 2009-01-22 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP2008539169A (ja) 2005-04-19 2008-11-13 イーライ リリー アンド カンパニー 疾患における免疫学的介入のための一価および多価合成多糖類抗原
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
WO2006117400A2 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
US20080193543A1 (en) * 2005-05-17 2008-08-14 Brown University Research Foundation Drug Delivery Formulations For Targeted Delivery
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
US7462698B2 (en) * 2005-07-22 2008-12-09 Y's Therapeutics Co., Ltd. Anti-CD26 antibodies and methods of use thereof
NZ564764A (en) 2005-07-25 2011-08-26 Emergent Product Dev Seattle B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007014327A2 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
EP1913398A2 (en) * 2005-08-09 2008-04-23 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
PT1957647E (pt) 2005-11-25 2015-06-01 Zoetis Belgium S A Oligorribonucleótidos imunoestimulantes
CA2631731A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8859209B2 (en) * 2006-01-12 2014-10-14 Carviar Aps Reimmunization and antibody design
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5524610B2 (ja) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
PL2027158T3 (pl) * 2006-05-02 2013-02-28 Carviar Aps Sposób immunizacji gatunków ptaków
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
EP2029169A2 (en) 2006-06-20 2009-03-04 Transgene S.A. Recombinant viral vaccine
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
NZ574311A (en) * 2006-07-24 2011-12-22 Tetralogic Pharm Corp Dimeric iap antagonists
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CN105168146A (zh) 2006-08-04 2015-12-23 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2387327T5 (es) 2006-09-26 2024-11-19 Access To Advanced Health Inst Composición de vacuna que contiene un adyuvante sintético
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
CA2665480C (en) 2006-10-04 2019-11-12 Shawn Defrees Glycerol linked pegylated sugars and glycopeptides
WO2008060791A2 (en) * 2006-10-13 2008-05-22 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
RU2373957C2 (ru) 2006-10-13 2009-11-27 Александр Метталинович Тишин Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
EP2644205B1 (en) 2007-04-12 2018-06-13 The Brigham and Women's Hospital, Inc. Targeting ABCB5 for cancer therapy
US8808747B2 (en) 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US20100179158A1 (en) * 2007-04-20 2010-07-15 Hoffman Charles S Inhibitors of cyclic amp phosphodiesterases
EP2152304B1 (en) * 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2160199A2 (en) * 2007-05-17 2010-03-10 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
ES2536907T3 (es) 2007-06-08 2015-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar el subtipo de un carcinoma hepatocelular
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
ES2627292T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
AU2009222056A1 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs
EP2385370A1 (en) 2008-04-10 2011-11-09 Massachusetts Institute of Technology (MIT) Methods for identification and use of agents targeting cancer stem cells
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
EP2132228B1 (en) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
DK2982753T3 (en) 2008-04-18 2018-09-03 Baxter Int Microsphere-based composition to prevent and / or reverse newly started autoimmune diabetes
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
CA2722589A1 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
EP2123748A1 (en) 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
EP2303888B1 (en) 2008-06-12 2015-05-06 President and Fellows of Harvard College Compounds for antimicrobial intervention
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
WO2010011347A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
JP2012503004A (ja) 2008-09-17 2012-02-02 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US8729053B2 (en) * 2008-09-22 2014-05-20 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nuclear factor kappa B pathway inhibitor composition and use of same
KR101810246B1 (ko) * 2008-10-08 2017-12-18 엑스진 파마슈티컬 인크. Ｇａｂａ 접합체 및 그의 사용 방법
EP2344632B1 (en) 2008-10-09 2022-12-28 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
DK3130923T3 (da) 2008-11-14 2020-05-11 Brigham & Womens Hospital Inc Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
EP3406244B1 (en) 2009-04-15 2023-06-07 BMG Pharma S.p.A. Compositions comprising zinc gluconate and taurine for mucosal or dermal disorders
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
AU2010242874B2 (en) 2009-04-30 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Schweinfurthins and uses thereof
MX336019B (es) 2009-05-14 2016-01-06 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares.
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
IN2012DN00352A (h) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011011092A1 (en) 2009-07-22 2011-01-27 University Of Massachusetts Methods and compositions to reduce oxidative stress
JP2013500313A (ja) 2009-07-30 2013-01-07 アンチセンス・ファーマ・ゲーエムベーハー 化学療法薬およびＴＧＦ−β系の阻害剤の組合せ
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
JP5756805B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
US20120244185A1 (en) 2009-09-16 2012-09-27 Vaxart ,Inc. Immunization strategy to prevent h1n1 infection
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US20110104138A1 (en) 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
EP2501716B1 (en) 2009-11-19 2015-01-21 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
KR20130088002A (ko) 2010-01-13 2013-08-07 재단법인 한국파스퇴르연구소 항-감염성 피리도(1,2-ａ)피리미딘
AU2011209399B2 (en) 2010-01-27 2014-04-10 Glaxo Group Limited Modified tuberculosis antigens
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
ES2596431T3 (es) 2010-05-04 2017-01-09 The Brigham And Women's Hospital, Inc. Antagonista de cadherina-11 para el tratamiento de fibrosis
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
WO2012018387A2 (en) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
EP2767298A3 (en) 2010-11-23 2014-10-01 Presage Biosciences, Inc. Therapeutic methods and compositions for solid delivery
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
CN103501810A (zh) 2010-12-22 2014-01-08 拜耳知识产权有限责任公司 牛物种中增强的免疫应答
CN103562186B (zh) 2011-01-12 2017-02-15 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
AU2012212105A1 (en) 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
CN103476931A (zh) 2011-02-03 2013-12-25 米尔纳医疗股份有限公司 Mir-34的合成模拟物
JP5973473B2 (ja) 2011-03-08 2016-08-23 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 脂質合成の複素環式モジュレーター
ES2666301T3 (es) 2011-03-09 2018-05-03 Cell Signaling Technology, Inc. Métodos y reactivos para crear anticuerpos monoclonales
CA2830503A1 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
PT2694549T (pt) 2011-04-08 2018-11-22 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro
US20140287043A1 (en) 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents
KR102052215B1 (ko) 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
BR112013032199A2 (pt) 2011-06-14 2017-12-12 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de utilização
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
US8759313B2 (en) 2011-08-03 2014-06-24 The Charlotte-Mecklenburg Hospital Authority Treatment of fibrosis using microRNA 19b
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013013061A1 (en) 2011-07-19 2013-01-24 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
US8324264B1 (en) 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
US10221454B2 (en) 2011-10-10 2019-03-05 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
RU2644243C2 (ru) 2011-10-20 2018-02-08 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы к cd22
EP2771043A4 (en) 2011-10-28 2015-04-29 Presage Biosciences Inc ACTIVE RELEASE PROCEDURE
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
ES2687954T3 (es) 2011-11-11 2018-10-30 Fred Hutchinson Cancer Research Center Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer
AU2012346214B2 (en) 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
SMT201900324T1 (it) 2012-02-07 2019-07-11 Infectious Disease Res Inst Formulazione migliorata di adiuvante comprendenti agonisti tlr4 e metodi per il loro uso
CA2863887C (en) 2012-02-09 2023-01-03 Population Diagnostics, Inc. Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
CN103251941A (zh) * 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
CA3209571A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP3505537A1 (en) 2012-05-07 2019-07-03 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EA034351B1 (ru) 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
CA2878829A1 (en) 2012-07-11 2014-01-16 University Of Vermont And State Agricultural College Methylation-controlled j protein (mcj) for treatment of liver disease and altering mitochondrial metabolism
RU2677639C2 (ru) 2012-07-13 2019-01-18 Шин Ниппон Биомедикал Лэбораториз, Лтд. Хиральный адъювант нуклеиновой кислоты
EP2885311B1 (en) 2012-08-18 2020-01-01 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2887942A4 (en) 2012-08-21 2016-08-31 Genesys Res Inst COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ANTHRACYCLIN-INDUCED CARDIOTOXICITY
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
CA2889055C (en) 2012-10-24 2024-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
WO2014074805A1 (en) 2012-11-08 2014-05-15 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
EP2931273A1 (en) 2012-12-12 2015-10-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating portal hypertension
EP2931272A1 (en) 2012-12-12 2015-10-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
JP6457999B2 (ja) 2013-03-14 2019-01-23 ザ チルドレンズ メディカル センター コーポレーション 処置に関してがんの対象を識別するためのｃｄ３６の使用
WO2014159060A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
AU2014233480B2 (en) 2013-03-15 2018-08-09 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160052985A1 (en) 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3013329B1 (en) 2013-06-25 2020-08-05 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for the treatment of persistent intracellular hbv infection
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
EP3077416B1 (en) 2013-12-06 2019-06-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
KR20160100329A (ko) 2013-12-20 2016-08-23 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물
JP6522007B2 (ja) 2014-01-07 2019-05-29 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 癌及びウイルス感染症に対する使用のための脂質合成の複素環式モジュレータ
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
MA39228A1 (fr) 2014-01-21 2017-06-30 Immune Design Corp Compositions à utiliser pour le traitement d'états allergiques
ES2978921T3 (es) 2014-02-20 2024-09-23 Vaxart Inc Formulaciones para administración en el intestino delgado
US10155950B2 (en) 2014-02-28 2018-12-18 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10590433B2 (en) 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof
EP3122369B1 (en) 2014-03-26 2022-08-31 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
WO2015149016A2 (en) 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP4116329A1 (en) 2014-05-27 2023-01-11 Academia Sinica Anti-her2 glycoantibodies and uses thereof
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
ES2875057T3 (es) 2014-09-17 2021-11-08 Us Health Anticuerpos anti-CD276 (B7H3)
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016061199A2 (en) 2014-10-14 2016-04-21 Research Development Foundation Methods for generating engineered enzymes
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN107592866A (zh) 2015-02-18 2018-01-16 佛蒙特大学及州农业学院 Mcj激动剂及其用途
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
ES2910049T3 (es) 2015-03-19 2022-05-11 Sagimet Biosciences Inc Moduladores heterocíclicos de la síntesis de lípidos
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US10718022B2 (en) 2015-04-15 2020-07-21 University Of Massachusetts Compositions and methods for XI chromosome reactivation
WO2016176155A1 (en) 2015-04-25 2016-11-03 Poznansky Mark C Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
CA2988299C (en) 2015-06-05 2023-10-31 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
CA2988761A1 (en) 2015-06-12 2016-12-15 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
EP3109257B1 (en) 2015-06-26 2021-01-06 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
CN108136005A (zh) 2015-07-10 2018-06-08 佛蒙特大学及州农业学院 用于治疗药物诱导的疾病和病症的mcj抑制剂
WO2017021266A1 (en) 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in porcine species
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
CA2995079A1 (en) 2015-08-20 2017-02-23 ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE Methods and compositions to treat liver diseases and conditions
US11819554B2 (en) 2015-09-17 2023-11-21 University Of Massachusetts Compositions and methods for modulating FMR1 expression
JP2018531229A (ja) 2015-09-18 2018-10-25 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル 癌の治療のための抗ｆｕｇｅｔａｃｔｉｃ剤の局所的送達
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
EP3383418B1 (en) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2 peptides for immunotherapy
AU2017210327A1 (en) 2016-01-20 2018-08-09 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
KR20180099887A (ko) 2016-01-20 2018-09-05 더 스크립스 리서치 인스티튜트 Ｒｏｒ2 항체 조성물 및 관련 방법
CA3014792A1 (en) 2016-02-16 2017-08-24 Carnegie Mellon University Compositions for enhancing targeted gene editing and methods of use thereof
US20200308590A1 (en) 2016-02-16 2020-10-01 Yale University Compositions and methods for treatment of cystic fibrosis
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2017177199A2 (en) 2016-04-08 2017-10-12 Iti Health, Inc. Plectin-1 binding antibodies and uses thereof
EP3452516A4 (en) 2016-05-04 2019-11-27 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
US12076397B2 (en) 2016-05-10 2024-09-03 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
IL319503A (en) 2016-05-16 2025-05-01 Access To Advanced Health Inst PEGylated liposomes and methods of use
RU2761870C2 (ru) 2016-05-16 2021-12-13 Инфекшес Дизис Рисёрч Инститьют Состав, содержащий агонист tlr, и способы применения
CA3025516A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
MX393217B (es) 2016-06-01 2025-03-11 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
US20190201414A1 (en) 2016-07-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
PH12019500191A1 (en) 2016-07-26 2022-04-11 Bayer Animal Health Gmbh Increased fertility in bovine species
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018049118A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018063472A1 (en) 2016-09-27 2018-04-05 Reyoung Corporation Compositions for treating parasitic diseases and methods thereof
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
AU2017355712B2 (en) 2016-11-07 2024-01-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
WO2018145109A1 (en) 2017-02-06 2018-08-09 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
EP3595636A4 (en) 2017-03-16 2021-01-13 Children's Medical Center Corporation ENGINEERED LIPOSOMES USED AS THERAPEUTIC AGENTS TARGETING CANCER
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
WO2018183383A1 (en) 2017-03-27 2018-10-04 Tenfold Technologies, LLC Anti-pathogen composition and methods of use thereof
EP3609332A4 (en) 2017-03-27 2021-06-02 Tenfold Technologies, LLC AGRICULTURAL METHODS AND COMPOSITIONS FOR PREVENTING OR CONTROLLING PLANT DISEASES
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
WO2018213612A1 (en) 2017-05-18 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
AU2018283973B2 (en) 2017-06-11 2025-04-24 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR20240096685A (ko) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
EP3649242A2 (en) 2017-07-06 2020-05-13 National University of Singapore Methods of inhibiting cell proliferation and mettl8 activity
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3651750A4 (en) 2017-07-14 2021-04-14 University of Massachusetts INFLAMMATION TREATMENT METHODS AND COMPOSITIONS
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
JP6817492B2 (ja) 2017-08-07 2021-01-20 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
IL319506A (en) 2018-04-09 2025-05-01 Checkmate Pharmaceuticals Inc Packaging of oligonucleotides in virus-like particles
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
ES2911428T3 (es) 2018-04-19 2022-05-19 Tvardi Therapeutics Inc Inhibidores de STAT3
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
CN118256490A (zh) 2018-06-06 2024-06-28 麻省理工学院 一种环状rna、组合物和治疗疾病的方法
WO2020001657A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
JP2021529001A (ja) 2018-06-29 2021-10-28 ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーＷｕｈａｎ Ｎｅｕｒｏｐｈｔｈ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ レーベル遺伝性視神経症を治療するための組成物及び方法
WO2020018949A2 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
SI3625368T1 (sl) 2018-08-08 2023-04-28 Pml Screening, Llc Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
JP7482874B2 (ja) 2018-08-22 2024-05-14 バカイン バイオセラピューティクス， リミテッド シクロスポリン組成物および使用方法
US20210338815A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods for enhancing triplex and nuclease-based gene editing
US20210340280A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
EP3860635A4 (en) 2018-10-04 2022-07-06 Rutgers, The State University of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020081737A1 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Compositions and methods for inducing intestinal stem cell regeneration
US20210340562A1 (en) 2018-10-19 2021-11-04 Board Of Regents, The University Of Texas System Engineered long interspersed element (line) transposons and methods of use
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
SG11202107708XA (en) 2019-01-18 2021-08-30 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
AU2020242043A1 (en) 2019-03-21 2021-10-14 Mitotherapeutix Llc Multivalent ligand clusters for targeted delivery of therapeutic agents
EP3952886A1 (en) 2019-04-10 2022-02-16 Elevatebio Technologies, Inc Flt3-specific chimeric antigen receptors and methods of using the same
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
JP2022541452A (ja) 2019-07-15 2022-09-26 ロバクサ がんの治療のための方法および組成物
CA3148735A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
US20210047423A1 (en) 2019-08-16 2021-02-18 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
AU2020336992A1 (en) 2019-08-30 2022-04-14 Yale University Compositions and methods for delivery of nucleic acids to cells
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
PH12022551211A1 (en) 2019-11-18 2023-10-02 Janssen Biotech Inc Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
US20230092615A1 (en) 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
MX2022011320A (es) 2020-03-13 2022-12-08 Janssen Biotech Inc Materiales y métodos para la unión de lectina tipo ig de unión a ácido siálico.
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
PH12022553032A1 (en) 2020-05-08 2024-05-13 Georgiamune Inc Akt3 modulators
CA3179423A1 (en) 2020-05-19 2021-11-25 Robert Alexander WESSELHOEFT Circular rna compositions and methods
CA3178726A1 (en) 2020-05-21 2021-11-25 Gregory LIZEE T cell receptors with vgll1 specificity and uses thereof
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
MX2023002480A (es) 2020-08-31 2023-05-18 Univ Yale "composiciones y métodos para el suministro de ácidos nucleicos a las células.
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
AU2021336217A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Live-attenuated rna hybrid vaccine technology
CN116615256A (zh) 2020-10-16 2023-08-18 乔治亚大学研究基金会 糖缀合物
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
TW202304986A (zh) 2021-03-24 2023-02-01 美商健生生物科技公司 靶向cd22及cd79b的抗體
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
CN115927472A (zh) 2021-07-05 2023-04-07 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
MX2024001597A (es) 2021-08-06 2024-02-15 Wuhan Neurophth Biotechnology Ltd Company Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4.
JP2024534053A (ja) 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体
EP4405392A1 (en) 2021-09-24 2024-07-31 Janssen Biotech, Inc. Proteins comprising cd20 binding domains, and uses thereof
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
JP2024542155A (ja) 2021-11-08 2024-11-13 オルナ セラピューティクス、インコーポレイテッド 環状ポリヌクレオチドを送達するための脂質ナノ粒子組成物
WO2023088227A1 (zh) 2021-11-16 2023-05-25 上海舶望制药有限公司 抑制血管紧张素原(agt)蛋白表达的组合物和方法
IL312704A (en) 2021-11-29 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Compositions and methods for inhibiting hepatitis B virus (HBV) protein expression
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
EP4514389A1 (en) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CN120092091A (zh) 2022-05-30 2025-06-03 上海环码生物医药有限公司 合成的环状rna组合物及其使用方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
AU2023338626A1 (en) 2022-09-09 2025-03-20 Yale University Proteolysis targeting antibodies and methods of use thereof
EP4583841A1 (en) 2022-09-09 2025-07-16 Access to Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
EP4602078A2 (en) 2022-10-11 2025-08-20 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2023404700A1 (en) 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
US11957676B1 (en) 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025052303A1 (en) 2023-09-08 2025-03-13 Beigene Switzerland Gmbh Circular rna and preparation methods thereof
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3823228A (en) * 1971-09-29 1974-07-09 Univ Illinois Tge virus vaccine
CH594444A5 (h) * 1972-12-04 1978-01-13 Gerd Birrenbach
FR2287216A1 (fr) * 1974-10-09 1976-05-07 Narcisse Guy Nouvelle forme galenique d'administration de medicaments et medicaments prepares sous cette nouvelle forme
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
DE2702952A1 (de) * 1976-02-04 1977-08-11 Medichemie Ag Kreislaufregulierendes, oral anzuwendendes arzneimittel
US4291016A (en) * 1976-07-27 1981-09-22 Sandoz Ltd. Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate
US4123519A (en) * 1976-08-17 1978-10-31 Philips Roxane, Inc. Injectable contraceptive vaccine and method
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
JPS58318B2 (ja) * 1977-07-11 1983-01-06 住友化学工業株式会社 制癌性物質の製造方法
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4203968A (en) * 1978-08-18 1980-05-20 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
US4152413A (en) * 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
US4152415A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Method of increasing the effectiveness of oral vaccination for swine dysentery
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
GB2058562B (en) * 1979-09-14 1983-11-30 Beecham Group Ltd Pharmaceutical compositions containing paracetamol and ascorbic acid
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
JPS5719660A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Microcapsule for immune reaction
JPS5719662A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Preparation of microcapsule reagent for immune reaction
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
IT1220979B (it) * 1981-06-04 1990-06-21 Lofarma Farma Lab Capsule contenenti un allergene e procedimento per la loro preparazione
IL63220A (en) * 1981-07-01 1985-09-29 Yeda Res & Dev Process for production of polyacrolein microspheres
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US4428925A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release glycerol trinitrate
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
JPS58209984A (ja) * 1982-05-28 1983-12-07 Japan Synthetic Rubber Co Ltd 粒子状重合体よりなる担体
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
DE3465888D1 (en) * 1983-06-22 1987-10-15 Univ Ohio State Res Found Small particle formation and encapsulation
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US4764359A (en) * 1984-05-25 1988-08-16 Lemelson Jerome H Drug compositions and their use in treating human or other mammalian patients
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4681722A (en) * 1985-10-07 1987-07-21 Owens-Corning Fiberglas Corporation Method of making a lineal structural member
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
WO1987006129A1 (en) * 1986-04-10 1987-10-22 Daratech Pty. Ltd. Vaccine and implant
PT85521B (pt) * 1986-08-11 1990-06-29 Innovata Biomed Ltd Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
NL8720442A (nl) * 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
RU2005104392A (ru) 2006-07-27
EP0706792A1 (en) 1996-04-17
ES2210268T3 (es) 2004-07-01
AU3343389A (en) 1989-10-05
KR0126823B1 (ko) 1998-04-01
DE68926828T2 (de) 1997-01-09
DK222490D0 (da) 1990-09-17
JPH03503892A (ja) 1991-08-29
GR3020569T3 (en) 1996-10-31
EP0333523B1 (en) 1996-07-17
DE68926828D1 (de) 1996-08-22
ZA892103B (en) 1990-01-31
NZ228376A (en) 1992-05-26
US5075109A (en) 1991-12-24
EP0333523A2 (en) 1989-09-20
AU633483B2 (en) 1993-02-04
CN1308937A (zh) 2001-08-22
DK175851B1 (da) 2005-04-04
RU2127118C1 (ru) 1999-03-10
WO1989008449A1 (en) 1989-09-21
ATE253901T1 (de) 2003-11-15
RU2250102C2 (ru) 2005-04-20
CN1043442A (zh) 1990-07-04
ATE140386T1 (de) 1996-08-15
EP1181929A2 (en) 2002-02-27
IL89602A0 (en) 1989-09-10
EP1181929A3 (en) 2003-04-23
CN1211080C (zh) 2005-07-20
KR900700084A (ko) 1990-08-11
IN169330B (h) 1991-09-28
HK38897A (en) 1997-04-04
ES2088890T3 (es) 1996-10-01
EP0333523A3 (en) 1990-01-31
EP0706792B1 (en) 2003-11-12
CA1340692C (en) 1999-08-03
JP2521827B2 (ja) 1996-08-07
CN1070697C (zh) 2001-09-12
IE960647L (en) 1989-09-18
DE68929499T2 (de) 2004-09-16
DK222490A (da) 1990-11-16
IE83868B1 (en) 2005-04-20
DE68929499D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
IL89602A (en) Microencapsulated compositions for potentiating an immune response and methods for the preparation thereof
BR8801242A (pt) Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ZA894728B (en) A new pharmaceutical formulation as well as a process for its preparation
IL84167A (en) Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
EP0497977A4 (en) Gastric preparation
PH21591A (en) Improved pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient and method of using said pharmaceutical composition
WO1987004076A1 (en) Low dosage of interferon to enhance vaccine efficiency
ZA878176B (en) Substituted alpha-amino acids,their preparation and pharmaceutical compositions containing them
EP0459666A3 (en) Medicaments against impotence
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
EP0203649A3 (en) Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis
IT1217445B (it) Composizione farmaceutiche orosolubili contenti acetilcisteina
ZA892877B (en) Azelastine-containing medicaments with controlled release of the active substance
NZ224116A (en) Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
NZ220932A (en) Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
HUT52388A (en) Process for producing pharmaceutical compositions comprising unsaturated fatty acids and selenium as active ingredient
IL84312A (en) Ifosfamide lyophilisate and its preparation
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
JPS5441320A (en) Slow release preparation and its manufacturing
IL96903A0 (en) Topical pharmaceutical compositions comprising a vitamin d3 derivative
MY101916A (en) Etoposide oral dosage form.
AU6461590A (h)
IL84777A (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
ZA862478B (h)

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed